Apellis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic treatments targeting the complement system. The company is dedicated to transforming the treatment landscape for debilitating diseases, with a particular focus on ophthalmology and rare diseases. Apellis is committed to advancing complement science to address unmet medical needs through its robust pipeline of clinical trials and approved products. With a keen emphasis on patient-centered approaches and community engagement, Apellis strives to deliver breakthrough therapies to improve patient outcomes.